Chiasma Inc (CHMA)’s Stock Is Buy After Today’s Huge Increase

September 17, 2017 - By Adrian Erickson

The stock of Chiasma Inc (NASDAQ:CHMA) is a huge mover today! The stock increased 4.35% or $0.1 on September 15, reaching $2.4. About 101,535 shares traded. Chiasma Inc (NASDAQ:CHMA) has declined 48.76% since September 17, 2016 and is downtrending. It has underperformed by 65.46% the S&P500.
The move comes after 9 months positive chart setup for the $58.46M company. It was reported on Sep, 17 by Barchart.com. We have $2.62 PT which if reached, will make NASDAQ:CHMA worth $5.26 million more.

Chiasma Inc (NASDAQ:CHMA) Ratings Coverage

Among 3 analysts covering Chiasma (NASDAQ:CHMA), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Chiasma had 6 analyst reports since August 10, 2015 according to SRatingsIntel. The stock has “Underweight” rating by Barclays Capital on Tuesday, January 17. The rating was downgraded by Barclays Capital to “Equal-Weight” on Monday, April 25. As per Monday, August 10, the company rating was initiated by William Blair. Cowen & Co initiated the stock with “Outperform” rating in Monday, August 10 report. Barclays Capital initiated Chiasma Inc (NASDAQ:CHMA) on Monday, August 10 with “Overweight” rating. The rating was downgraded by William Blair on Monday, April 18 to “Market Perform”.

More important recent Chiasma Inc (NASDAQ:CHMA) news were published by: Streetinsider.com which released: “Chiasma, Inc. (CHMA) Announces Agreement with FDA Under SPA for New Phase 3 …” on August 10, 2017, also Marketwatch.com published article titled: “2.50”, Globenewswire.com published: “Chiasma Names Mark J. Fitzpatrick Chief Executive Officer” on September 30, 2016. More interesting news about Chiasma Inc (NASDAQ:CHMA) was released by: Globenewswire.com and their article: “Chiasma Recognizes Acromegaly Awareness Day with New Resources for Patients …” with publication date: November 01, 2016.

Chiasma, Inc. is a biopharmaceutical company. The company has market cap of $58.46 million. The Firm is engaged in developing and commercializing oral forms of therapies that are available only by injection. It currently has negative earnings. Using its Transient Permeability Enhancer technology platform, the Company is developing oral therapies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: